The role of genetic risk factors, diet, and gut microbiota in type 1 diabetes mellitus, pancreas and pancreatic islet transplantation.
Agnieszka ZawadaMarzena Skrzypczak-ZielinskaSarah GondekPiotr WitkowskiAnna M RychterAlicja E Ratajczak-PawłowskaMarek KarczewskiAgnieszka DobrowolskaIwona Krela-KaźmierczakPublished in: Endokrynologia Polska (2024)
Despite advances in insulin delivery and glucose monitoring technology, prevention of the progression of secondary complications in patients with type 1 diabetes (T1DM) remains a challenge. Beta cell replacement therapy in the form of islet or pancreas transplantation can restore long-term normoglycaemia with sustained periods of insulin independence among T1DM patients. However, the same genetic, behavioural, or gut microbiota-related factors that promoted autoimmunity and primary islet destruction may also affect the function of transplanted islets and the ultimate results of transplant procedures. In such cases, identifying genetic risk factors and modifying behavioural factors and those related to gut microbiota may be beneficial for the outcomes of transplant procedures. Herein, we review related literature to the identified current gap in knowledge to be addressed in future clinical trials.
Keyphrases
- risk factors
- replacement therapy
- glycemic control
- type diabetes
- clinical trial
- genome wide
- end stage renal disease
- cell therapy
- ejection fraction
- chronic kidney disease
- copy number
- newly diagnosed
- healthcare
- systematic review
- smoking cessation
- prognostic factors
- physical activity
- single cell
- insulin resistance
- randomized controlled trial
- patient reported outcomes
- mesenchymal stem cells
- metabolic syndrome
- skeletal muscle
- phase ii
- drug induced